Verona Pharma plc (VRNA) stock plunged to an all-time low of $5.76 on Monday as its lead chronic inflammatory lung disease treating drug failed to show desired results in the phase 2 study. This is the first huge dip for the London-based biopharmaceutical company since IPO. The company’s lead drug for treating chronic obstructive pulmonary … Continue reading Verona Pharma stock plunges to all time low on disappointing trial